These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3398448)

  • 61. [Clinical features and up-to-date therapy of hypertensive emergencies].
    Meyer FP
    Dtsch Med Wochenschr; 2004 Apr; 129(14):768; author reply 768-9. PubMed ID: 15042498
    [No Abstract]   [Full Text] [Related]  

  • 62. [Treatment of hypertensive crisis by the sublingual route: a call for prudence].
    Medraño Martínez JC; Gómez Cerezo J; Cobo Mora J; Juárez Alonso S
    Rev Clin Esp; 1989 Mar; 184(4):209. PubMed ID: 2740552
    [No Abstract]   [Full Text] [Related]  

  • 63. Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice.
    Jegasothy R; Paranthaman S
    J Obstet Gynaecol Res; 1996 Feb; 22(1):21-4. PubMed ID: 8624887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Hypertensive crisis].
    Wenger U; Zimmerli L
    Praxis (Bern 1994); 2009 Feb; 98(3):115-20; quiz 121. PubMed ID: 19180435
    [No Abstract]   [Full Text] [Related]  

  • 65. [A 73-year-old patient with hypertensive crisis. Was the use of calcium antagonist nifedipine justified?].
    Wenzel UO; Pfalzer B; Meinertz T; Stahl RA
    Internist (Berl); 1999 Feb; 40(2):205-9. PubMed ID: 10097979
    [No Abstract]   [Full Text] [Related]  

  • 66. INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study.
    Bertram M
    Lancet; 2000 Dec; 356(9245):1926; author reply 1928-9. PubMed ID: 11130403
    [No Abstract]   [Full Text] [Related]  

  • 67. [Arterial hypertension in the elderly: a therapeutic problem].
    Rico L; Velasco J
    Rev Clin Esp; 1989 Nov; 185(8):55-6 p.. PubMed ID: 2696004
    [No Abstract]   [Full Text] [Related]  

  • 68. Risks and benefits of calcium antagonists.
    Lichtlen PR
    Lancet; 1995 Oct; 346(8980):962. PubMed ID: 7564741
    [No Abstract]   [Full Text] [Related]  

  • 69. [Ca antagonists].
    Takasaki I; Umemura S
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():127-32. PubMed ID: 11028307
    [No Abstract]   [Full Text] [Related]  

  • 70. [T-type calcium channel antagonists].
    Shimizu M; Hongo K
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():282-5. PubMed ID: 11028340
    [No Abstract]   [Full Text] [Related]  

  • 71. [The structural-functional status of the myocardium and central and regional hemodynamics in patients with essential hypertension under the influence of treatment with korinfar and its combination with anaprilin].
    Polivoda SN; Fushteĭ IM; Khalil AA
    Lik Sprava; 1995; (9-12):32-4. PubMed ID: 8983784
    [No Abstract]   [Full Text] [Related]  

  • 72. [Therapy of the hypertensive crisis].
    Grabensee B
    Dtsch Med Wochenschr; 1985 Nov; 110(45):1738-40. PubMed ID: 2865121
    [No Abstract]   [Full Text] [Related]  

  • 73. [Role of calcium antagonists in the treatment of arterial hypertension].
    Belousov IuB
    Kardiologiia; 1991 Apr; 31(4):5-9. PubMed ID: 2067182
    [No Abstract]   [Full Text] [Related]  

  • 74. [Cardiac insufficiency: current aspects of treatment].
    Vitola D; Costa R; Rodrigues R
    Arq Bras Cardiol; 1989 Sep; 53(3):143-6. PubMed ID: 2698132
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension.
    Liu W; Liu Y; Fu J
    Pak J Pharm Sci; 2019 Sep; 32(5(Special)):2419-2422. PubMed ID: 31894027
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Usefulness of long-acting Ca antagonist in hypertensive patients with metabolic syndrome].
    Takishita S
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():607-10. PubMed ID: 17458290
    [No Abstract]   [Full Text] [Related]  

  • 77. Calcium channel blockers and hypertension: 2. Safety issues.
    Epstein M
    Hosp Pract (1995); 1996 Dec; 31(12):93-6, 99-104. PubMed ID: 8969683
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FDA approves i.v. calcium-channel blocker.
    Thompson CA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1686. PubMed ID: 18768991
    [No Abstract]   [Full Text] [Related]  

  • 79. Sublingual nifedipine in human pregnancy.
    Gallery ED; Györy AZ
    Aust N Z J Med; 1997 Oct; 27(5):538-42. PubMed ID: 9404584
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sublingual nifedipine controversy in drug delivery.
    Schumann D
    Dimens Crit Care Nurs; 1991; 10(6):314-20. PubMed ID: 1935527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.